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ABSTRACT
Objective: The purpose of this study was to compare the effectiveness of the rhizome extract against inflammatory markers such as tumor necrosis 
factor (TNF)-alpha and prostaglandin E2 (PGE2) with meloxicam in patients with osteoarthritis at knee.
Materials and Methods: This study designed two phases as follows: The preparation of rhizome extract in a capsule dosage form which was then 
followed by double-blind clinical trials, randomized controlled, pre- and post-test design (18 cases) using the WOMAC scores for pain, to markers of 
inflammation using an enzyme-linked immunosorbent assay method.
Results: The results did not reveal any significant differences in pain scores, stiffnesses, and physical function impairment between the intervention 
(the rhizome extract) and control groups (meloxicam), it either did not reveal any significant differences in the parameters of inflammatory marker 
TNF alpha and PGE2 among the groups.
Conclusion: The rhizome extract had the same effect on pain, stiffness, physical interference as meloxicam, and on PGE2 as well as on the inflammatory 
marker TNF-alpha. Therefore, this extract can be used as an alternative herbal medicine for osteoarthritis.
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INTRODUCTION
Osteoarthritis is a progressive disease characterized by the degeneration 
of cartilage and joint tissue changes that cause pain, stiffness, and 
disability [1]. The disease is common in the elderly causing disability 
in old ages [2,3]. The incidence of osteoarthritis increases with age 
and is estimated about 80% of the population aged 65 years proven 
radiologically. A report released by the Indonesian Ministry Health in 
2013 stated that the national prevalence in Indonesia reached 24.7%. 
Specifically, for several regions in Indonesia reported high prevalence, 
in Pontianak (89.91% cases) and the highest is at age 55–60 years 
(28.93%). The high prevalence of osteoarthritis disease requires serious 
attention to prevention, especially on the level of disability at old ages [1].
Management of osteoarthritis treatment is aimed at controlling 
pain and pain and improves function and quality of life. The use of 
nonsteroidal anti-inflammatory drug (NSAID) is effective in treating 
chronic pain in the knee. Meloxicam which is classified as NSAID has 
an analgesic function, anti-inflammatory, and antipyretic. However, 
long-term use has an impact on the side effects, particularly on the 
gastrointestinal system, including dyspepsia, gastric mucosal irritation, 
and bleeding [2]. The utilization of medicinal plants for the treatment 
of hereditary has been used and provided good results. Utilization 
empirically Kaempferia galanga by society as a drug is effective for 
nausea, cough, anti-inflammatory, colds, and sore [4-6]. This benefit 
is reinforced that the powder contains essential oils can provide 
analgesic and anti-inflammatory effects, especially in arthritis, The 
main chemical constituents of the essential oil is a compound of Ethyl 
p-methoxycinnamate [7,8].
This study indicates that K. galanga rhizome extract can be an 
alternative for traditional medicine in relieving symptoms and clinical 
signs of inflammation on osteoarthritis such as pain, swelling, stiffness, 
and disability in addition to the provision of chemical drugs such as 
meloxicam.
MATERIALS AND METHODS
The study design includes two stages: The first stage of the preparation 
and manufacture of rhizome extract in a capsule dosage form which was 
then followed by double-blind randomized controlled clinical trials.
Population and sample
There are 35 people respondents in this study. Respondents are people 
with osteoarthritis of the knee in sub-district Puskesmas Tamalanrea 
Biringkanaya Makassar Indonesia. The diagnosis of osteoarthritis is 
based on the criteria of the American College of Rheumatology 2016. 
A radiological examination performed by a physician radiologist.
RESULTS AND DISCUSSION
Result
Table 1 shows the characteristics of respondents by gender as the 
highest percentage of women with 94.3% of respondents aged under 
60 years (60.0%). The education level of respondents was mostly in the 
category of compulsory education to 12 years (94.3%) whereas 88.6% 
of respondents did not work. The mean body mass index (BMI) of 
respondents fall into the category of obesity and all parameters of blood 
tests are normal except in the category of prostaglandin E2 (PGE2) and 
tumor necrosis factor (TNF)-alpha. These values are above normal.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Table 2 shows the average examination results of both the intervention 
and control groups. The mean BMI in both groups shows above 
normal values which enter the category of obesity. Meanwhile, blood 
examination results of both groups show normal values except for 
the levels of PGE2 and TNF-alpha value. Inspection parameters in the 
two groups have equal value because they did not differ significantly 
(p>0.05) in all parameters. This indicates that the data at the time of 
the initial baseline between the intervention and control groups are 
normally distributed and homogeneous.
Table 3 shows the increase in ureum levels within the two groups. 
The control group exhibits a significant increase (<0.05) whereas 
the increase in the intervention group was not significant (p>0.05). 
Nonetheless, value ureum levels for both groups fall into the category 
of normal. Serum glutamate oxaloacetate transaminase (SGOT) in the 
control group decreased significantly (p<0.05), whereas the intervention 
group experienced an increase but not significant (p>0.05). The value 
of SGOT levels for both groups falls into the category of normal.
The PGE2 biomarker value for the intervention group decreased prior 
and after the administration of rhizome extract but this impairment 
is not significant (p>0.05). In contrast, the control group experienced 
a rise although not significant (p>0.05). The main values in the two 
groups, however, were not different (p>0.05).
The TNF-alpha biomarker value for the intervention group increased 
significantly (P <0.05) but not for the control group. However, when 
compared to the difference in the mean values before and after the two 
groups, the results were not different (p>0.05).
Discussion
Population research overview
Weight loss is a risk factor for the incidence of osteoarthritis of the 
knee [9]. The greater the person’s weight, the more at risk for knee 
osteoarthritis [10]. The results, in this study, showed that the majority of 
the study sample radiographically classified as obese. This data indicate 
that the status of obesity affects the severity of osteoarthritis. There are 
two samples with a BMI >25 were considered obese (obese II). Both 
of these samples dropped out of the study when the intervention took 
place on the grounds in which the administered dose was not able to 
reduce the pain. This happens because the drug dose does not take into 
account the intervention given sample weight so that the possibility of 
inadequate doses given.
Table 1: Characteristics and examination results mean respondents (n=35)








≤High school undergraduate 94.3 (5.7)
Work
Work 88.6 –




IMT 26.04±3.61 18.5–23 kg/m2
hb 12.93±0.95 p=(12.0–14.0 g/dl), L=(14.0–16.0 g/dl)
ureum 25.37±7:50 10–50 mg/dl
creatinine 0.62±0:12 0.6–1.2 mg/dl
Uric acid 5:38±1:49 2.4–6.0 mg/dl
SGOT 22.94±7:14 <31 U/L
SGPT 20.66±9.68 <32 U/L
PGE2 746.95±627.91 200–400 pg/ml
TNF-alpha 1371.51±1587.66 0–100 pg/ml
TB: Total bilirubin, BB: Bilirubin, IMT: Intima-media thickness, SGOT: Serum glutamate oxaloacetate transaminase, SGPT: Serum glutamate pyruvate transaminase, 
PGE2: Prostaglandin E2, TNF: Tumor necrosis factor
Table 2: Average of examination respondents in intervention group (n=18) and controls (n=17)
Parameters Intervention group (X±XD) Control group (X±XD) p value Normal values
Age 57.78±8.63 58.94±8.98 0699* -
TB 149.11±6:09 148.71±6.83 0854* -
BB 59.67±10:02 56.11±10:55 0314* -
IMT 26.80±3.82 25.24±3:30 0207* 18.5–23 kg/m2
hb 12.81±1:07 13:06±0.83 0441* p=(12.0–14.0 g/dl), L=(14.0–16.0 g/dl)
ureum 27.56±8:21 23:06±6:08 0155** 10–50 mg/dl
creatinine 0.62±0:12 0.61±0:12 0704** 0.6–1.2 mg/dl
Uric acid 5:51±1:20 5:25±1.77 0150** 2.4–6.0 mg/dl
SGOT 22:00±6.70 23.94±7.64 0290** <31 U/L
SGPT 19.89±5.75 21:47±12.74 0631** <32 U/L
PGE2 688.90±671.25 808.41±592.70 0509** 200–400 pg/ml
TNF-alpha 1245.20±1526.86 1505.26±1685.96 0692** 10–100 pg/ml
*Independent t-test; **Mann–Whitney, TNF: Tumor necrosis factor, PGE2: Prostaglandin E2, TB: Total bilirubin, BB: Bilirubin, IMT: Intima-media thickness, 
SGOT: Serum glutamate oxaloacetate transaminase, SGPT: Serum glutamate pyruvate transaminase
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K. galanga extract effect against PGE2
PGE2 is an important mediator of the inflammatory process and is 
produced at sites of inflammation by Cyclooxygenase-2 (COX-2) [10]. 
This study showed decreased levels of PGE2 after intervention by 
K. galanga rhizome extract, but this decrease was not statistically 
significant. The rhizome extract administered in mice in two doses; 
600 mg/kg and 1200 mg/kg, respectively. Doses significantly give anti-
inflammatory and anti-analgesic activities, respectively, compared to 
mice treated with aspirin (100 mg) and codeine (5 mg). The rhizome 
extract was given only in the dose of 160 mg. Results were not achieved 
in this study likely due to the very low given doses. There are several 
studies on the effects of rhizome extract against inflammatory and 
analgesic on mice and the obtained results essentially significantly 
reduced inflammatory and analgesic effects.
PGs play a key role in the pain experience of injury, inflammation, 
malignancies, and many other conditions [10]. PGs have a central role 
in the pathophysiology of arthritis and pain. Chondrocytes isolated 
from patients with osteoarthritis generate 50-fold more PGE2 than 
chondrocytes from patients without osteoarthritis. PG stimulates the 
release of matrix metalloproteinase (MMP), which can contribute to 
joint disorders. PGs can also have an effect on the osteoclast/osteolysis. 
COX-2 transcription settings for inflammatory arthritis is influenced by 
a variety of inflammatory cytokines including interleukin-1β(IL-1β) 
and TNFα. Meloxicam and COX-2 selective inhibitors prevent PGE2 
production in response to IL-1 and TNFα in rheumatoid synovium. 
IL-1β may stimulate pathways inducible nitric oxide (NO), thus 
increasing the NO. NO can act as secondary intermediaries that mediate 
sensitization nociceptors in sensory neurons, induces the production 
of PG through upregulation of COX-2. When MMP is activated, it causes 
cartilage degradation and chondrocyte apoptosis triggered. NO-
triggered chondrocyte apoptosis is facilitated by the specific inhibition 
of PGE2 and COX-2 [10].
CONCLUSION
There were no significant differences in the parameters of inflammatory 
markers that TNF-alpha and PGE2 between the intervention (K. galangal 
rhizome extract) and control groups (meloxicam); the rhizome extract 
has the same effect on pain, stiffness, physical interference with 
meloxicam, and the PGE2 and the inflammatory marker TNF-alpha. 
Therefore, the similar effect of K. galanga rhizome extract to the effect 
with the meloxicam can be used as a replacement for osteoarthritis 
drugs.
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